Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 3, 2026

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

View original at finance.yahoo.com
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts Quick Read Novo Nordisk (NVO) cut Wegovy and Ozempic prices up to 48% in India due to generic semaglutide competition, while shares have fallen 43% over the past year to $36.98 as 2026 guidance signals -5% to -13% adjusted sales growth; the c…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Phase 3 data showed 14.2% weight loss in type 2 diabetes patients for CagriSema

    60% confidence
  • Wegovy HD achieved an average weight loss of 20.7% over 72 weeks

    60% confidence
  • 2026 guidance signals -5% to -13% adjusted sales growth

    60% confidence
  • CagriSema (cagrilintide plus semaglutide) is expected to receive FDA obesity decision around end of 2026/early 2027

    60% confidence

Data points we hold from this source

Novo Nordisk · stock price 52 week low35.12 USD
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts: Source | Via News | vianews.market